The global advanced wound care market is set to witness steady growth, reaching approximately USD 17,302.8 million by 2035 from USD 12,385.4 million in 2025, with a CAGR of 3.4% over the forecast ...

Merakris Therapeutics. Cellular, Acellular, Matrix-like Products (CAMPs) Summit hosted first awards ceremony, and recognized Merakris Therapeutics’ Scientist in “Best Comparat ...

The Europe Advanced Wound Care Market is experiencing robust growth, driven by the rising prevalence of chronic wounds, an aging population, increasing surgical procedures, advancements in wound care ...

MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

PHOENIX, Feb. 12, 2025 /PRNewswire/ -- BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in wound healing ... Membrane Wrap™ in venous leg ulcers.

Subjects who achieve wound bed preparation will then be ... EscharEx outperformed other non-surgical standard-of-care treatments for VLUs. "MediWound commences Phase III trial for venous leg ulcers ...

Natalin is a decellularized dehydrated amnion derived tri-layer graft and Acelagraft™ is a decellularized dehydrated amnion derived bi-layer graft. Both Natalin and Acelagraft™ are indicated for use ...

IRVINE, CA / ACCESS Newswire / February 28, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, ...

IRVINE, CA / ACCESS Newswire / February 28, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous ...